A Clinical-Stage Psychedelics Biotech Company

PharmaTher Holdings Ltd.

OTCQB: PHRRF | CSE: PHRM

Corporate Presentation

April 2022

This presentation of PharmaTher Holdings Ltd. (“PharmaTher”) contains "forward-looking information", which may include, but is not limitedto, statements with respect to anticipated business plans or strategies of PharmaTher, the anticipated date of completion of researchstudies, the timing of any drug trials, the success of its clinical trials, the ability to enter into licenses, acquisitions or collaborations to enhanceits drug development platform, the success of any such licenses, acquisitions or collaborations and the ability to use the information relatingto, or obtain patents or other intellectual property protection on, data and clinical trials generated directly by PharmaTher or through suchlicenses, acquisitions or collaborations, and the success or stage of development of discoveries or medicines. Often, but not always,forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates","forecasts", "intends", "anticipates", or "believes" or variations (including negative variations) of such words and phrases, or state that certainactions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements involve knownand unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of PharmaTher to bematerially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Factorsthat could cause actual results to differ materially from those anticipated in these forward-looking statements are described under thecaption “Risk Factors” in PharmaTher’s management’s discussion and analysis for the period of November 30, 2021 (“MD&A”), dated January27, 2022, which is available on PharmaTher’s profile at www.sedar.com. Forward-looking statements contained herein are made as of thedate of this presentation and PharmaTher disclaims, other than as required by law, any obligation to update any forward-lookingstatements whether as a result of new information, results, future events, circumstances, or if management's estimates or opinions shouldchange, or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and futureevents could differ materially from those anticipated in such statements. Accordingly, the reader is cautioned not to place undue reliance onforward-looking statements.

Forward Looking Statements

COMMERCIALIZE novelKETAMINE solutions

Focus

UNLOCK potential ofKETAMINE

Purpose

EXPAND adoption ofKETAMINE

Grow

KetamineMicroneedle PatchKetamine

IV / Injection

Repurpose

Delivery

Formulations

Mental Health

Neurological

Pain

Surgery

About Us

KETARX™

Procedures

Partnerships

About Ketamine

50 years of clincal use

FDA approved for anesthesia andprocedural sedation

Commonly delivered by intravenous,intramuscular injection, intranasal

NMDA receptor antagonistresponsible for anesthetic, analgesicand anti-depressant activity

Global Opportunity

Anesthesia / SedationSurgeries - General, Emergency, Pediatric

Procedures - MRI, Dental, Endoscopy, Biopsies, Cosmetic

Mental HealthDepression, Suicidal ideation,

Substance abuse, PTSD, Bipolar, OCD

PainNeuropathic, CRPS, Fibromyalgia, Cancer,

various chronic/acute conditions

Neurological DisordersParkinson's disease, ALS, Seizures

500 M

1.5 B 700 M

10 M

- Various dosage/delivery forms- Partner with pharma, clinics, hospitals, HCPs

Commercialize KETARX™

- Depression, Pain, Parkinson's disease, ALS, Seizures, Procedures

Expand clinical uses

- ANDA and FDA 505(b)(2)- Patent protection, FDA orphan drug designation

Obtain regulatory approvals

- Microneedle patch for all type of drugsCollaborations

KetamineMicroneedle Patch

KetamineIV / Injection

KETARX™

Strategy

Not FDA approved. Not for sale.

Additional Expected Milestones Clinical and product development updates Patents and exclusive regulatory designations Collaborations and commercial licensing

Expected Q2-2022Follow-on study results with ketamine forParkinson's disease

Study results - microneedle patch Ketamine

MDMA

DMT

MilestonesExpected H2-2022

Submit FDA application of KETARX™ IV /Injection via ANDA regulatory pathway

FDA acceptance for Phase 3 study withKETARX™ IV for Parkinson’s disease

FDA/EU acceptance for Phase 2 studywith KETARX™ Patch for depression/pain

Study results - KETABET™ (ketamine+betaine) Pain

Depression

KETARX™ IV

KETARX™ IV

Indication Pre-Clinical Phase 1 Phase 2 Phase 3Product

This is our plan to make our food delivery service exclusive and top-notch.

AmyotrophicLateral Sclerosis

Anesthesia &Sedation

Parkinson'sDisease

Current 12 Months

KETARX™ IV

KETARX™ MN Patch Depression

KETARX™ MN Patch

*Complex Regional Pain Syndrome; FDA ODD for ketamine only, not with MN patch

PHARMAPATCH™ Partnerships

Seek ANDA Approval

Granted FDA OrphanDrug Designation

Granted FDA OrphanDrug Designation

IV – Intravenous / InjectionMN - Microneedle

Pain*

Product Pipeline

KETARX™ IV / Injection

- Obtain FDA approval via ANDA pathway in 2022 - Off-label use for mental illness and pain

Initial target is anesthesia/sedation

- Clinical studies in Parkinson's disease, ALS- Seek FDA approval via 505(b)(2) regulatory pathway

Expand to neurological disorders

- Ketamine IV is regularly on the FDA drug shortages list- Near-term revenue and partnerships opportunities- Establishes footprint for new ketamine products

Position for growth

Not FDA approved. Not for sale.

KETARX™ Patch

- Offers a safe and improved efficacy over other dosage forms - Pain-free, easy administration and improves compliance- Deliver ketamine from 10 minutes up to 30 days- Tamper-proof: avoid patient misuse, abuse, diversion

Next generation ketamine product

- Mental health, neurological and pain disorders- FDA approvals via 505(b)(2) regulatory pathway

Unlocks new indications

- Ketamine clinics and hospitals use (alternative to IV/injection)- Out-patient / Home use becomes a possibility

Significantly expands utilizationKetamine'Hydrogel'

Microneedle PatchNot FDA approved. Not for sale.

How KETARX™ Patch Works?

Ketamine inreservoir

Ketamine diffusesthrough the swollen

microneedles

Ketamine-loadedreservoir is

completely dissolved

Insterstitial fluidsoaks into

microneedle

Ketamine diffuses through theswollen microneedles and

facilitates permeation into thedermal microcirculation

PHARMAPATCH™ Technology

- Drug combinations, controlled and rapid delivery- Control PK profile & drug load (high/low)- Avoid first-pass metabolism, higher bioavailability

Different dosing / delivery options

- Pain-free, patient compliance, safety and usability- Allow for treatment at home

Patient improvement

- Controlled-substances (psychedelics), small and large molecule drugs, biologics, etc

Partnering opportunities

Relationships Collaborations

Licenses

Granted Patents, PCTs, Provisional PatentsDeliveryMicroneedle patchand hydrogelcomposites fordrugs/APIs

RepurposeCompositions andmethods for ketaminein Parkinson’s Disease,Amyotrophic lateralsclerosis

FormulationMethod andcomposition fordecreasing sideeffects and addictivedisorder of ketamine

Regulatory and Patent Portfolio

Ketamine- Amyotrophic lateral sclerosis- Complex Regional Pain Syndrome - Status Epilepticus (Seizures)

3 Granted

20 ProcessManufacturing processfor ketamine solution

Team

Fabio Chianelli

Founder, CEO, President atRevive Therapeutics Ltd.

Founder, Chairman, CEO

Carmelo Marrelli

CFO of TSX, CSE, OTCQBlisted companies

Chief Financial Officer

Dr. Owen Van Cauwenberghe

Director, Research at Eli Lilly CADDirector, Pharma R&D at Accucaps

VP, Pharmaceutical Development

Dr. Maurizio Fava, MD

Psychiatrist-in-Chief, MGHDirector Clinical , MGH

Clinical Advisor, Depression

Professor Ryan Donnelly

Chair of PharmaceuticalTechnology, QU Belfast

Technical Advisor, MN patch

Dr. Robert A. Hauser, MD

Director, USF Parkinson'sDisease and MD Center

Clinical Advisor, Parkinson's

Fabio Chianelli

Founder, CEO, President atRevive Therapeutics Ltd.

Founder, Chairman, CEO

Dr. Bev Incledon

EVP, CSO, Ironshore Pharma25 years drug development

Director

Entrepreneur and investor

Christian ScovennaDirector

Investor, Biotech/Real estate

Carlo SansaloneDirector

Management Advisors Board of Directors

88,169,065**Issued & Outstanding Common Shares

4,749,000**Stock options outstanding

16,908,000**Warrants outstanding

Financial Snapshot

* As at November 30, 2021** As of March 31, 2022

~ $14 million* Cash and investments

~ 19%* Insiders Ownership

PHRRF

3,499,000 @ $0.10 (expires July 2025)1,000,000 @ $0.18 (expires March 2027)250,000 @ $0.91 (expires Sept 2026)

16,875,000 @ $0.80 (expires Sept 2026)33,000 @ $0.10 (expires July 2022)